American Society of Clinical Oncology (ASCO)
Journal of Clinical Oncology (JCO) Podcast
The Journal of Clinical Oncology Podcast presents analyses and discussions centered on the latest findings published in ASCO's flagship Journal of Clinical Oncology. Host Dr. Davide Soldato facilitates interviews and scholarly discourse on the most impactful published findings. The Journal of Clinical Oncology Podcast is the trusted resource that empowers you to integrate cutting-edge evidence into clinical practice. The year's fellows interview authors and summarize the top Journal of Clinical Oncology articles in the series, JCO Article Insights.
Author
American Society of Clinical Oncology (ASCO)
Category
Podcast website
Latest episode
Jun 11, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Better Patient-Reported Outcomes After Autologous Breast Reconstruction Compared to Implant-Based Reconstruction Study 28.03.2017 8:40
Patients who had autologous reconstruction had higher satisfaction with breasts and well-being than patients who had implant-based reconstruction, but both groups experienced substantial physical morbidity.
Drugs Don't Work in Patients Who Don't Take Them 24.03.2017 8:40
This podcast describes the results and implications of the article published by Landier et al, describing the relationship between 6-MP ingestion habits and outcomes, as well as adherence, among children with acute lymphoblastic leukemia.
Pembrolizumab is Safe and Active in Platinum- and Cetuximab-Refractory Head and Neck Squamous Cell Carcinoma 22.03.2017 9:42
By Amanda Psyrri The findings of KEYNOTE-055 are summarized and compared to other immunotherapy studies in recurrent/metastatic head and neck squamous cell carcinoma. Related Article: Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Long-Term Follow-up of AF-001JP: A Phase I/II Study of Alectinib in ALK-Positive NSCLC 15.03.2017 9:42
Podcast re: 'Three-year Follow-up of an Alectinib Phase 1/2 Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP' by Tamura et al.
Late Relapse in Hodgkin Lymphoma Persisting Even at 20 Years: Implications for Therapeutic Intensity and Disease Biology 28.02.2017 9:26
This podcast discusses the JCO article, "Late Relapse of classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7-HD12 Trials" by Paul Jan Bröckelmann, et al. which demonstrates that late relapses are seen in a small fraction of early stage good risk Hodgkin lymphoma patients, which increase in incidence up to 20 years and do not appear to plateau, and examines the implication...
Intensification of Consolidation Therapy for Acute Myeloid Leukemia by the Addition of Clofarabine to Cytarabine Improves Relapse-Free Survival 21.02.2017 11:12
By Kenneth Bradstock This podcast describes a clinical trial of clofarabine in consolidation therapy for adults with acute myeloid leukemia. Related article: Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission
Characterizing the Patterns of Clonal Evolution in Ibrutinib-Treated CLL: A Roadmap for Continued Progress 13.02.2017 8:40
Dr. Wiestner highlights characteristics of ibrutinib resistant CLL as reported by Woyach and colleagues and discusses how these data refine the management of CLL in the area of targeted therapy and can stratify patients for future clinical trials.
Prevalence of Germline Mutations in Individuals With Colorectal Cancer as Determined Using a Multi-Gene Panel Test 30.01.2017 8:19
Summary and discussion of JCO paper by Yurgelun at al. using a 25-gene panel to demonstrate a nearly 10% germline mutation rate in colorectal cancer patients independent of high-risk factors.
Financial Barriers to Cancer Care for Patients Obtaining Insurance on the Federal Exchange 11.01.2017 7:34
By Stacie B. Dusetzina Considering the role of network coverage on access to accredited cancer institutions and potential out-of-pocket costs for patients. Related Article: Access to Accredited Cancer Hospitals Within Federal Exchange Plans Under the Affordable Care Act
Mindfulness-Based Interventions in Oncology: Not for Everyone? 21.11.2016 7:06
By Linda E. Carlson This podcast discusses the target study in the context of other research on mindfulness-based interventions for cancer patients and survivors, providing a critique and suggestions for clinical interpretation and future research. Related Article: Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial
The Impact of Oral Targeted Therapies on the Cost of Care for Patients With Chronic Lymphocytic Leukemia 21.11.2016 11:01
By Christopher R. Flowers Modeling studies like the one presented by Qiushi Chen and colleagues can project where needs and opportunities exist to address the pricing structure of medications and the selection of management strategies in CLL. Related Article: Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
Watching Nivolumab's Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma 14.11.2016 7:58
This podcast provides commentary on a large dataset describing the expected frequency, severity and kinetics of immune-related adverse events associated with nivolumab monotherapy and the expected use of corticosteroid supportive therapy together with observations relating to the associations between immune adverse events, corticosteroid use and efficacy.
Getting to the Heart of the Matter: Biomarkers for the Assessment of Trastuzumab-Induced Cardiac Dysfunction 26.10.2016 11:13
By Deepa Rangachari This podcast focuses on the use of trastuzumab in adjuvant therapy for early stage, Her2-positive breast cancer and ongoing efforts to identify predictive and prognostic biomarkers for the assessment of treatment-related cardiac toxicity. Related Article: Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients W...
Listen to Your Patients 03.10.2016 12:58
If you are an oncologist and think that it isn't part of your job to listen to your patients talk about depression, I urge you to re-consider. As Sullivan and colleagues show, depression can be lethal.
Chemotherapy Induced Peripheral Neuropathy: A Novel Method of Exploration 14.08.2016 10:26
This podcast highlights the innovative methodology employed in this study to determine risk factors for chemotherapy induced peripheral neuropathy, as well as implications of the findings to clinical practice and future investigation of immune mechanisms of this toxicity.
Changes in the Epidemiology of AIDS-Related Kaposi's Sarcoma and Lymphomas: How This Informs the Clinician 08.08.2016 9:26
This podcast will assist readers in understanding the clinical implications of the paper by Yanik and colleagues. The paper describes the occurrence of Kaposi's sarcoma and lymphoma in the era of effective anti-HIV therapy where patients appear to be doing well from the standpoint of HIV clinical assessment, but continue to develop cancers associated with AIDS.
Implicit Racial Bias Affects Key Aspects of Physician Communication 14.07.2016 9:00
Implicit bias affects oncologists and their patients - a few steps can help
Nivolumab Monotherapy is Safe and Active in Hematologic Malignancies 14.07.2016 9:21
This podcast is a discussion of a clinical trial by Lesokhin et al which evaluated nivolumab monotherapy in patients with relapsed or refractory hematologic malignancies.
Minimizing Frailty in Cancer Survivors: A Meaningful Goal for All Ages 13.07.2016 7:11
This podcast discusses the prevalence of and risk factors associated with a phenotype of accelerated aging among ALL survivors. Measurement and implications of frailty/pre-frailty are discussed.
1q Gain, a Prognostic Biomarker in Nephroblastoma, and What's Next? 11.07.2016 9:02
This podcast comments on two independent pediatric studies on both sides of the Atlantic showing the relevance of 1q gain in poor prognosis Wilms tumors which raises the perspectives for therapeutic modifications.
Therapy Impacts Long-Term Survival for Patients in Germany With Heritable Retinoblastoma 05.07.2016 10:39
While ten-year overall survival has increased for German patients with heritable retinoblastoma, treatment modalities including radiation and/or chemotherapy can impact overall survival.
Dexamethasone and High-Dose Methotrexate in High-Risk B Cell Acute Lymphoblastic Leukemia—Where Should We Go From Here? 01.07.2016 10:32
The Children's Oncology Group study led by Larsen et al. showed that children and young adult patients with high-risk B cell acute lymphoblastic leukemia benefit from receiving high-dose methotrexate during interim maintenance 1 and that those aged 1 to 9 years benefit from receiving dexamethasone for 14 days during induction.
Unraveling the Significance of Mismatch Repair Deficiency in Women With Endometrioid-type Endometrial Adenocarcinoma 20.06.2016 10:39
This podcast discusses the study by McMeekin and colleagues regarding their analysis of the prognostic and predictive implications of mismatch repair deficiency status among a tissue sample registry cohort of 1,024 endometrioid-type endometrial adenocarcinomas.
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.